Clinical Trial Update: A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke [Phase 3]

View source ↗

Summary

Phase 3 study comparing asundexian to apixaban in atrial fibrillation to prevent stroke or systemic embolism has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Stroke

Drugs mentioned

• Apixaban (apixaban)
• Asundexian (asundexian)

Snippet

Sponsor: Bayer | Conditions: Prevention of Stroke or Systemic Embolism, Atrial Fibrillation | Phase 3 | Status: TERMINATED | Results posted: 2024-12-09